Biohaven
251 articles about Biohaven
-
Biohaven Announces Proposed Public Offering Of Common Shares - Jan. 28, 2020
1/28/2020
Biohaven Pharmaceutical Holding Company Ltd., a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, announced that it has commenced an underwritten public offering of $250 million of its common shares.
-
Clinical Catch-Up: Jan 20-24
1/27/2020
The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look. -
Biohaven's Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General
1/22/2020
Biohaven Pharmaceutical Holding Company Ltd. announced that the U.S. Food and Drug Administration has notified its collaborators at the Sean M. Healey & AMG Center for Amyotrophic Lateral Sclerosis at Massachusetts General Hospital that they may proceed with clinical investigation of verdiperstat, Biohaven's novel myeloperoxidase inhibitor, in ALS.
-
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office
12/5/2019
U.S. Pat. No. 10,485,791 was issued on November 26, 2019 by the U.S. Patent and Trademark Office for the composition of matter of troriluzole
-
Clinical Catch-Up: November 4-8
11/11/2019
It was a busy week for clinical trial updates for the first week of November. Here’s a look. -
Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
11/5/2019
Over 700 patients enrolled in the T2 Protect AD Study evaluating troriluzole in symptomatic treatment of mild-to-moderate Alzheimer's disease
-
Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
11/4/2019
Kleo is a novel immuno-oncology company spun out of Yale University developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
9/10/2019
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered vazegepant (formerly BHV-3500) for the acute treatment of migraine
-
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial
8/7/2019
Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine
-
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled
7/22/2019
Biohaven Pharmaceutical Holding Company Ltd. announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease, is progressing on timelines with more than 400 subjects enrolled and over 180 subjects randomized to study treatment.
-
Clinical Catch-up for July 15-19
7/22/2019
Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more. -
Biohaven's Nurtec 505(b)2 Application for Amyotrophic Lateral Sclerosis Affected by Issues Related to Apotex Plant: Complete Response Letter (CRL) Received From FDA Related to Isolated Drug Substance Supply Used in Bioequivalence Study
7/19/2019
Biohaven Pharmaceutical Holding Company Ltd. announced that it has received a Complete Response Letter from the FDA for the 5052 application seeking approval for NURTEC™ for ALS.
-
Clinical Catch-Up for July 8-12
7/15/2019
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look. -
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
7/11/2019
Rimegepant Zydis® Oral Fast-Dissolve Tablet (ODT) Phase 3 results demonstrate rapid and sustained benefits for the acute treatment of migraine
-
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Needs In Acute Treatment Of Migraine
7/11/2019
Research suggests patients define effective migraine therapies as reliable pain relief that enables them to return to their lives. Current treatments limit the ability for some patients to reach their treatment goals due to nonresponse to standard therapies and side effects.
-
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
6/24/2019
Rimegepant leads the meeting with the most presentations for an oral small molecule CGRP receptor antagonist, including 14 late breakers